In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (PRQR), with a price target of $25.00. The company’s shares closed last Tuesday at $5.49, close to its 52-week low of $4.84.
According to TipRanks.com, Nakae is a 1-star analyst with an average return of -5.4% and a 40.0% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and Arcturus Therapeutics.
ProQR has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.07 and a one-year low of $4.84. Currently, ProQR has an average volume of 225.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
